Modified DCF (mDCF, docetaxel cisplatin 5FU) for patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) unfit to DCF: A retrospective study

Authors :: Philippe Zrounba
Eve-Marie Neidhardt
Marc Poupart
Antoine Ramade
Clara Delaruelle
Alexis Ambrun
Clémentine Daveau
Jérôme Fayette
Philippe Ceruse
Source :: Journal of Clinical Oncology. 32:e17018-e17018
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: e17018 Background: DCF is the standard chemotherapy for induction in LASCCHN. Its toxicity reserves it to younger patients (pts) without comorbidity and of PS 0-1. In gastric cancer mDCF demonstrat...

Subjects :: Oncology
Cisplatin
Cancer Research
Chemotherapy
medicine.medical_specialty
business.industry
medicine.medical_treatment
Locally advanced
Cancer
Retrospective cohort study
medicine.disease
Comorbidity
Docetaxel
Internal medicine
Toxicity
Medicine
business
medicine.drug

Full Text Access

Tools